TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate ...
WILMINGTON, Del.--(BUSINESS WIRE)--Apr 30, 2026-- The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP ® (capivasertib) in combination with …